These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9354926)

  • 1. Biomarker end-points in cancer chemoprevention trials.
    Boone CW; Kelloff GJ
    IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
    Bostwick DG; Aquilina JW
    J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis.
    Boone CW; Kelloff GJ
    Cancer Surv; 1998; 32():133-47. PubMed ID: 10489626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
    Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
    Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
    Einspahr JG; Alberts DS; Gapstur SM; Bostick RM; Emerson SS; Gerner EW
    Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):37-48. PubMed ID: 8993796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia.
    Boone CW; Kelloff GJ
    J Cell Biochem Suppl; 1994; 19():10-22. PubMed ID: 7823580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
    Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
    J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surrogate end-point biomarkers in chemopreventive drug development.
    Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
    IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
    Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
    Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.
    Lam S; Xu X; Parker-Klein H; Le Riche JC; Macaulay C; Guillaud M; Coldman A; Gazdar A; Lotan R
    Int J Oncol; 2003 Dec; 23(6):1607-13. PubMed ID: 14612933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents.
    Boone CW; Bacus JW; Bacus JV; Steele VE; Kelloff GJ
    J Cell Biochem Suppl; 1997; 28-29():1-20. PubMed ID: 9589346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
    Singletary SE; Atkinson EN; Hoque A; Sneige N; Sahin AA; Fritsche HA; Lotan R; Lu T; Hittelman WN; Bevers TB; Stelling CB; Lippman SM
    Clin Cancer Res; 2002 Sep; 8(9):2835-42. PubMed ID: 12231524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
    J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention with theaflavins of rat esophageal intraepithelial neoplasia quantitatively monitored by image tile analysis.
    Boone CW; Stoner GD; Bacus JV; Kagan V; Morse MA; Kelloff GJ; Bacus JW
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1149-54. PubMed ID: 11097221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research.
    Marshall JR
    IARC Sci Publ; 2001; 154():191-8. PubMed ID: 11220658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy.
    Boone CW; Kelloff GJ; Steele VE
    Cancer Res; 1992 Apr; 52(7):1651-9. PubMed ID: 1551096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials.
    Fabian CJ; Zalles C; Kamel S; Zeiger S; Simon C; Kimler BF
    J Cell Biochem Suppl; 1997; 28-29():101-10. PubMed ID: 9589354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.